Roswell Park Cancer Institute receives “outstanding” distinction from NCI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ROSWELL PARK CANCER INSTITUTE received an “outstanding” distinction from NCI, which renewed its Cancer Center Support Grant and extended its Comprehensive Cancer Center designation, following an in-depth peer review. Roswell Park will receive $19 million with the core grant covering a five-year period.

“With this renewal comes recognition from our peers from cancer centers around the nation of Roswell Park’s excellence in conducting innovative research, distinguished education programs and exemplary patient care,” said RPCI President and CEO Donald Trump.

The panel of peer reviewers from other NCI-designated centers wrote: “Under the exemplary leadership of the Center Director and with the continued involvement of the outstanding and productive Senior Leaders and commitment of the Institution… this established Cancer Center is well positioned to continue its contributions to the national mission to understand and eliminate cancer.”

New York State Governor Andrew Cuomo and Congressman Brian Higgins, along with other state and local leaders, joined Trump for Tuesday’s announcement at the 116-year-old cancer center.

YOU MAY BE INTERESTED IN

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login